
· Executive Brief
Prostate Cancer Awareness Month 2026
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Leadership signal
Recognition becomes useful when leaders inspect the real route.
The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Prostate cancer care depends on what happens after the first PSA test
Prostate cancer awareness campaigns usually focus on getting men screened. The research gathered for this brief suggests that many failures happen later, after a test result, a referral or a decision to monitor rather than treat. A community outreach program for Black men in southeastern Michigan screened 340 men at community events.[15] Of the 28 men with an elevated PSA, 17 did not complete follow-up.[15]
Monitoring has its own gaps. In a real-world active surveillance cohort of 864 men, surveillance adequacy, defined by regular PSA testing and periodic biopsy, was 38% among non-Hispanic Black men compared with 50% among non-Hispanic White men.[1] Black men in that cohort also had higher 10-year prostate cancer-specific mortality, at 5.6% versus 1.4%.[1] Those differences point to the reliability of follow-up, not only to access at the front door.
Shared decision-making is a practical lever as well as an ethical one. In national survey data on 10,778 U.S. men aged 55 to 69, racial disparities in PSA screening were no longer significant after adjusting for shared decision-making and other factors.[4] Decision aids designed for underserved men improved how informed and satisfied participants felt about their choice.[6]
This brief adds the research base to the executive guidance already on this page. It covers burden and outcomes, the continuum from outreach to surveillance and survivorship, access to urology and monitoring, equity and trust, the people who navigate the pathway and public communication. Each section separates what studies found from what leaders may choose to do. None of it is individual medical advice. Leaders can use it to choose one prostate cancer handoff to strengthen first, and to decide which measure will show whether the change held.
Current evidence
What the research says about screening, surveillance and outcomes
Racial gaps appear at diagnosis and during monitoring. In the Henry Ford Health active surveillance cohort, 38% of the 864 men were non-Hispanic Black.[1] Black men presented with more advanced disease and progressed to treatment more often, at 45% versus 36%, a 1.46-fold higher risk.[1] The authors concluded that targeted strategies are needed to address lower follow-up adequacy and other disparities on surveillance.[1] Black men also had higher rates of grade group 2 disease at entry, at 29% versus 18%.[1] For health systems, those figures make surveillance follow-up an equity measure as well as a quality measure.
Active surveillance is common but not stable for every man. A Korean multicenter cohort of 716 men on surveillance across 12 institutions found that 224 (31.3%) transitioned to active treatment over a mean follow-up of 28.4 months.[9] The most frequent reason was pathologic reclassification, at 60.3% of transitions.[9] Patients with poorer functional status or greater comorbidity tended to remain on surveillance rather than proceed to treatment.[9] Real-world surveillance decisions therefore reflect patient condition as well as disease findings, which complicates simple benchmarks.[9]
Protocols vary, and that variation shows up in outcomes. Three institutions with distinct surveillance protocols reported five-year surveillance retention of 53.2%, 79.8% and 59.1%.[11] Treatment transition occurred in 23.2%, 18.1% and 44.0% of patients, respectively.[11] Final pathology did not differ among men who had surgery, and the authors called for evidence-based standardization.[11] Multi-site systems may find similar variation among their own urology practices.
Eligibility for surveillance also varies by place. Among 27,075 men with biopsy-confirmed prostate cancer across 51 Korean hospitals, 6,586 (24.3%) were potentially eligible for active surveillance under a broad definition.[13] Eligibility decreased from 27.6% in 2010 to 22.0% in 2020.[13] Urban residents had higher eligibility than rural residents, at 26.4% versus 20.5%.[13] The study did not examine why, so local data are needed before drawing conclusions about similar gaps.
Surveillance has a different cost and resource profile from immediate treatment. A matched Ontario analysis found that men on surveillance had far fewer cancer clinic visits per patient-year than men not on surveillance, at 1.7 versus 26.7.[14] Mean overall cost per patient-year was $6100 for surveillance cases and $10,400 for men not on surveillance, in 2023 Canadian dollars.[14] The authors concluded that surveillance has cost savings potential for low-risk disease.[14]
Figure 1
Follow-through, not just screening, separates outcomes
Percent of men reaching or missing the reported pathway step, as reported in each study. Values are copied from the cited studies [1], [3], [15]; none is estimated.
Data note. Each pair of bars from the same study can be compared within that study; comparisons across the three studies are indirect because settings, populations and measures differ.
Limitation. The follow-up value rests on 28 men, and the attendance values come from a feasibility pilot outside the United States.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Adequate surveillance follow-up, non-Hispanic Black men | 38% | Active surveillance cohort of 864 men, Henry Ford Health, 1995 to 2023 | [1] |
| Adequate surveillance follow-up, non-Hispanic White men | 50% | Same cohort; adequacy defined as at least one PSA test a year and a biopsy every four years | [1] |
| Elevated PSA at community events without completed follow-up | 60.7% | 17 of 28 men with elevated PSA among 340 screened, southeastern Michigan, March 2022 to June 2023 | [15] |
| Attended targeted health check, test-first invitation | 22.9% | Men at higher risk invited by four primary care networks in North East London | [3] |
| Attended targeted health check, telephone-first invitation | 11.2% | Same pilot; telephone consultation followed by hospital-based PSA testing | [3] |

Continuum of care
Where the prostate cancer pathway breaks between outreach, results and surveillance
The prostate cancer pathway has several handoffs that rarely sit with one owner. It runs from outreach and a screening conversation to a PSA result, follow-up of an elevated result, imaging and biopsy, a treatment or surveillance decision, years of monitoring and survivorship care. Each step depends on the previous one being completed and communicated. A missed step often leaves no visible trace until the patient returns with more advanced disease.
Follow-up of an elevated PSA is a critical and fragile handoff. In the Michigan outreach program, 60.7% of men with an elevated PSA from community screening events did not complete follow-up.[15] Men with PSA levels at or above 4 ng/ml were contacted for follow-up, yet most still did not complete it.[15] The authors called for further efforts to reduce barriers to screening and follow-up.[15] Community screening that is not linked to a tracked clinical follow-up route can find risk without resolving it.
Surveillance needs active tracking, not passive scheduling. The Henry Ford Health study defined adequacy as at least one PSA test each year and a biopsy at least every four years.[1] By that measure, fewer than half of Black men and only half of White men were adequately followed.[1] A surveillance program that cannot show who is overdue for testing is not fully under management. A simple registry with due dates, owners and reminder status is the operating foundation for safe surveillance at scale.
Monitoring also uncovers other needs. A tertiary cancer center cohort of 744 men on surveillance, followed for a median of 108 months, found that 99 men (13%) experienced a complication related to benign prostatic hyperplasia.[10] The authors noted that definitive surgical management was infrequently pursued even after complications.[10] They called for systematic assessment and evidence-based management of urinary symptoms in the surveillance population.[10]
Survivorship is the last handoff and often the least connected. In a digital survivorship program, 14 Black men rated the program highly, and 12 of 13 with item-level data endorsed offering it as standard care.[2] Participants described limited awareness of the program at diagnosis and reliance on individual clinicians or incidental opportunities to learn about it.[2] The authors distinguished program availability from meaningful access and called for earlier referral and integration into routine care.[2]
Figure 3
Why the pathway breaks
People
- No navigator assigned to elevated results
- Limited clinician time for shared decision-making
- Few trained community partners
Process
- Elevated results from community events not tracked to completion
- Survivorship support not offered at diagnosis
- Inconsistent referral criteria to urology
Technology
- Inaccurate family history coding
- No registry of surveillance patients due for testing
- Decision aids unavailable or unfamiliar
Environment
- Rural distance from imaging and urology
- Neighborhood deprivation
- Historical mistrust of health systems
Policy
- Variable surveillance protocols across sites
- Invitation methods that depend on telephone contact
- Limited funding for navigation roles
Measurement
- Surveillance adequacy not measured
- Follow-up of elevated PSA not reported
- Results not stratified by race or community
Unranked qualitative cause-and-effect diagram for the outcome in the box: Men with an elevated PSA or on active surveillance are not followed to the next step, and Black men are least likely to be adequately followed Causes are assembled from the cited literature [1], [2], [3], [7], [9], [10], [11], [13], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | No navigator assigned to elevated results; Limited clinician time for shared decision-making; Few trained community partners |
| Process | Elevated results from community events not tracked to completion; Survivorship support not offered at diagnosis; Inconsistent referral criteria to urology |
| Technology | Inaccurate family history coding; No registry of surveillance patients due for testing; Decision aids unavailable or unfamiliar |
| Environment | Rural distance from imaging and urology; Neighborhood deprivation; Historical mistrust of health systems |
| Policy | Variable surveillance protocols across sites; Invitation methods that depend on telephone contact; Limited funding for navigation roles |
| Measurement | Surveillance adequacy not measured; Follow-up of elevated PSA not reported; Results not stratified by race or community |
Access
Invitations, referral patterns and geography shape access to urology
How men are invited changes whether they come. A feasibility pilot in four primary care networks in North East London invited 2,400 men at higher risk, of whom 398 (16.6%) attended.[3] Attendance was higher when men were offered community-based PSA testing first than when they were offered a telephone consultation first, at 22.9% versus 11.2%.[3] The authors concluded that test-first invitations improved engagement.[3]
Data quality limits risk-based outreach. In the same pilot, only 51.4% of participants met eligibility criteria because family history was coded inaccurately in primary care records.[3] Age and ethnicity data were sufficient to identify men at higher risk, but family history coding was unreliable.[3] Health systems planning targeted outreach can audit the fields they intend to use before they send invitations. Men who did not meet eligibility criteria were still offered PSA tests in the pilot, which kept the invitation from becoming a dead end.[3]
Referral rules determine who reaches urology. A survey of 107 primary care physicians across 25 health centers in Portugal found that most urology referrals were triggered by abnormal transrectal ultrasound findings, at 72%, rather than elevated PSA alone, at 16.8%.[7] National guidelines were the primary influence on practice for 75.7% of respondents.[7] The authors highlighted gaps in evidence-based referral criteria and a need for clearer national guidance.[7]
Geography shapes eligibility for less intensive care. In the Korean national cohort, active surveillance eligibility ranged from 16.9% to 29.3% across 17 districts.[13] Rural residents were less often eligible than urban residents.[13] Rural patients may face both later diagnosis and longer travel for the monitoring that surveillance requires, which makes local imaging, laboratory and telehealth capacity part of the access plan. Executives can map where surveillance patients live against where monitoring services are offered.
Clinician practice also varies within one system. In the Michigan program, 78 of 129 providers (60%) who completed an assessment routinely offered PSA screening to men aged 55 to 69.[15] Between 2018 and 2023, the system’s overall PSA screening rate rose from 8.2% to 12.7%.[15] Provider education sessions were part of the outreach effort, alongside community events and focus groups.[15] Clinician-level variation of that size suggests that access depends partly on which clinician a man happens to see.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Navigate across services
Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Navigate across services | Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Disparities for Black men persist across the pathway
Black men face higher risk at multiple points. In the London pilot, Black men had lower prior PSA testing than White men, at 55.7% versus 82.5%, and higher deprivation.[3] The authors concluded that disparities affecting Black men highlight the need for tailored outreach.[3] In the Henry Ford Health cohort, Black men on surveillance had lower follow-up adequacy and 5.9-fold higher odds of prostate cancer-specific mortality.[1]
Shared decision-making may narrow screening gaps. In the national survey analysis, 46% of eligible men reported a PSA test in the past year, and estimated shared decision-making was a significant predictor of screening.[4] After adjusting for shared decision-making and covariates, racial disparities in screening were no longer significant.[4] Only Asian American men showed a significantly lower likelihood of screening after shared decision-making compared with White men.[4]
Decision aids can work in underserved settings. A randomized trial surveyed 100 patients at a primary care clinic in Newark, New Jersey.[6] Decision aid recipients were nearly 6 times more likely to strongly agree they received as much information as they wanted.[6] They were also more than 4 times more likely to be happy with their decision about PSA screening.[6] The authors concluded that the aid improved informed decision-making in an underserved urban community.[6] There were no significant differences in age, race, education or insurance status between the trial groups.[6]
Trusted community settings extend reach. In a barbershop-based HIV stigma reduction pilot in Tennessee, 50 barbers enrolled across 26 barbershops and reached an estimated 4,464 client encounters.[8] Barbers facilitated an estimated 3,096 referrals and rated themselves highly effective as health ambassadors.[8] That program addressed HIV rather than prostate cancer, but it shows how trained barbers can connect Black men to services.[8] A prostate health partnership built on the same model would need a defined clinical route for every referral it generates.
Representation matters after diagnosis too. Black men in the digital survivorship study emphasized the need for greater representation of Black men and outreach through trusted community networks.[2] Peer connection was especially important in reducing isolation and making sensitive concerns easier to discuss.[2] Health systems can ask whether their survivorship and support offerings reflect the men they serve. Asking Black patients and community partners directly is the most reliable way to find out.

Human infrastructure
Navigators, primary care teams and community partners carry the pathway
Primary care clinicians hold the first conversation for most men. In the Portuguese survey, 80.4% of primary care physicians explained PSA testing, but only 64.5% consistently discussed its benefits and risks or explored patient preferences.[7] Only 6.5% had used decision aids, while 72% were unfamiliar with them.[7] Those gaps describe a training and tools problem rather than a lack of awareness. Protected visit time and ready access to decision aids are practical responses. Less experienced physicians were more likely to cite national guidelines as their main influence.[7]
Decision support can extend clinician capacity. A randomized trial of 367 middle-aged and older men compared standard education and counseling with the same support plus a machine learning recommendation.[5] Men who received the recommendation reported significantly lower decisional conflict and higher decision satisfaction.[5] When the system recommended accepting screening, 50.7% chose to accept, compared with 24.2% in the control group.[5]
That influence cuts both ways. In the same trial, only 17.8% of men who received a not now recommendation chose to accept screening.[5] Leaders deploying digital decision support need governance over how recommendations are generated and reviewed, because patients appear to follow them closely. The authors described the tool as complementing, not replacing, clinical consultation.[5] Clinical leaders can review such tools before deployment and monitor whether they change screening patterns in unintended ways.
Community partners are part of the workforce. The Michigan program held 4 focus groups, distributed about 1000 brochures and took part in 45 community events.[15] It also ran multiple educational sessions for health system providers.[15] In the Tennessee barbershop program, 67 barbers completed training, showing how community roles can be developed deliberately.[8] Of 57 barbers contacted after training, 50 enrolled in the pilot.[8]
Navigation is the missing link in several studies. The Michigan outreach found that most men with elevated PSA did not complete follow-up, which suggests that education and screening alone were not enough.[15] Survivorship participants relied on individual clinicians to learn about support programs.[2] A named navigator who tracks each elevated result and each surveillance patient is a practical response that follows directly from these findings. Navigator caseloads can be sized to the volume of elevated results and surveillance patients, and reviewed as that volume grows.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Navigation continuity
Where does ownership become unclear as people move among information, evaluation, services, and follow-through?
- Candidate local measure
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Navigation continuity | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Navigation continuity | Where does ownership become unclear as people move among information, evaluation, services, and follow-through? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable prostate cancer pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Every elevated PSA assigned to a named navigator | Men with elevated results never reach urology | Oncology service line director with nurse navigation lead | Share of elevated results with completed follow-up within a set window |
| Surveillance registry with overdue alerts | Men on surveillance miss monitoring | Urology medical director | Surveillance adequacy by race and site |
| Decision aids and time for shared decision-making in primary care | Screening decisions made without information | Primary care medical director | Documented shared decision-making for eligible men |
| Accurate risk-factor data for targeted outreach | High-risk men not invited or wrongly invited | Population health and health information management leads | Audit of ethnicity and family history fields |
| Standardized surveillance protocol across sites | Different sites manage similar men differently | Chief medical officer with urology leadership | Protocol adoption and retention by site |
| Survivorship referral at diagnosis | Men learn about support by chance | Cancer center survivorship lead | Share of new diagnoses offered survivorship support |
| Community partnerships with defined referral routes | Outreach generates interest without a next step | Community health director | Referrals from community partners completed |
Control points derived from the cited evidence [1], [2], [3], [4], [6], [7], [11], [15] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating about prostate cancer in ways men can act on
Public messages during Prostate Cancer Awareness Month can do more than encourage screening. They can explain what happens after a test, who will call with results and what monitoring involves. The Michigan program built its educational materials from focus groups with Black men about their perceptions of prostate cancer and screening.[15] That approach lets the community shape the message before it is distributed. Messages can also name the follow-up step plainly, so a man who receives an elevated result knows what happens next and who will contact him.
Living with uncertainty is part of the experience. A meta-synthesis of 13 qualitative studies found that men on active surveillance live with a lack of certainty, which can drive ongoing worry and loss of agency.[12] Re-establishing agency alleviated stress, promoted resilience and supported confidence in surveillance.[12] The authors noted concern that almost 40% of men discontinue surveillance without clinical indications.[12]
Clear explanations support confident choices. In the Newark decision aid trial, recipients were more than 5 times more likely to accept definitive therapy after a hypothetical diagnosis.[6] In the machine learning trial, men reported greater perceived support and more adequate advice.[5] Communication materials that explain options in plain language can be paired with conversations rather than replace them. Testing materials with the men who will use them helps confirm that the language is clear.
Peer voices and trusted messengers matter. Survivorship participants valued peer connection and wanted to remain connected to a monthly videoconference community.[2] Barbers in the Tennessee pilot described normalizing health discussion as everyday shop talk.[8] Organizations can partner with survivors, barbers, faith leaders and community groups to carry messages that people trust. Those partners also hear concerns that rarely reach clinic staff, which makes them a source of feedback as well as outreach.
The executive role is to make communication part of the operating design. That means confirming that every elevated result is communicated and followed, that surveillance patients know when they are due and that survivorship support is offered at diagnosis. It also means reporting results by race and community, including the men who did not return. The evidence in this brief suggests those are the points where awareness becomes reliable care.

Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Prostate Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Prostate Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Month observance
Turn Prostate Cancer Awareness Month into accountable action.
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Prostate Cancer Awareness Month, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Prostate Cancer Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Finocchiaro A, Chiarelli G, Stephens A, Viganó S, Bertini A, Cusmano N, et al. Active Surveillance for Prostate Cancer in “Real-World” Setting: Exploring Racial Disparities. Journal of Racial and Ethnic Health Disparities. 2026;13(4):3265-3273. https://doi.org/10.1007/s40615-025-02497-4
- 2.Okedara O, Ilie G, Brodovsky M, Mason RJ, Rendon R, Kokorovic A, et al. From Availability to Access: A Mixed-Methods Study of Digital Prostate Cancer Survivorship Support for Black Men. Current Oncology. 2026;33(9):543. https://doi.org/10.3390/curroncol33090543
- 3.Haider M, Dumagat A, Green JS, Allchorne P, Wong AS, Ashraf A, et al. Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London. BJGP Open. 2026;10(2):1-12. https://doi.org/10.3399/bjgpo.2025.0219
- 4.Joung HH, Martin DN, Jones RA. Bridging the Gap: The Role of Shared Decision-Making in Addressing Racial and Ethnic Disparities in Prostate-Specific Antigen Screening. Oncology Nursing Forum. 2026;53(2):57-67. https://doi.org/10.1188/26.onf.e26535281
- 5.Lin YT, Huang YC, Liu CK, Cho HY, Chen M. Web-Based Personalized Machine Learning Recommendations to Enhance Shared Decision-Making in Prostate-Specific Antigen Screening: Randomized Controlled Trial. JMIR Aging. 2026;9:e83238. https://doi.org/10.2196/83238
- 6.Gurushankar M, Khawaja IM, Shah RR, Kim D, Mattes MD, Natale-Pereira A, et al. Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population. Urology Practice. 2026;13(2):145-155. https://doi.org/10.1097/upj.0000000000000925
- 7.Oliveira B, Lopes L, de Oliveira Branco S, Oliveira S, Granja A, Gonçalves F, et al. Exploring shared decision-making in prostate cancer screening within primary health care settings in Portugal: a cross-sectional study. BMC Primary Care. 2026;27(1). https://doi.org/10.1186/s12875-026-03409-z
- 8.Perkins JM, Hu RX, Humphrey M, Hull SJ, von Kraut K, King N, et al. Cutting Out Stigma: Findings From a Pilot Implementation Trial of a Barbershop‐Based HIV Stigma Reduction and Health Promotion Intervention in the Southern United States. Journal of the International AIDS Society. 2026;29:1-14. https://doi.org/10.1002/jia2.70195
- 9.Choi J, Lee CU, Jeon SS, Byun SS, Joung JY, Ahn H, et al. Predictors of active surveillance discontinuation in prostate cancer: Large Korean multicenter cohort study. Investigative and Clinical Urology. 2026;67(5):459-467. https://doi.org/10.4111/icu.20260118
- 10.Monaco A, Koh S, Guo A, Garcia RS, Ellis T, Palasi S, et al. Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort. Urologic Oncology: Seminars and Original Investigations. 2026;44(10):789-795. https://doi.org/10.1016/j.urolonc.2026.07.007
- 11.Ko YH, Ryu JH, Kim YB, Shin TJ, Kim BH. Does protocol heterogeneity in active surveillance influence clinical outcomes? Insights from a multicenter prostate cancer cohort. Investigative and Clinical Urology. 2026;67(2):170-177. https://doi.org/10.4111/icu.20250460
- 12.Briggs RJ, Dunn J, Chambers SK, Jakimowicz S, Green A, Heneka N. The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis. Journal of Cancer Survivorship. 2026;20(4):1462-1479. https://doi.org/10.1007/s11764-025-01748-x
- 13.Ko YH, Kim SW, Son NH. Active surveillance could apply to one-quarter of Korean prostate cancer cases: Insights from a 27,075-patient cohort. Prostate International. 2026;14(2):127-131. https://doi.org/10.1016/j.prnil.2025.12.004
- 14.Seung SJ, Bayani J, Nguyen L, Liu N, Gatley J, Wong A, et al. Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance. Cancers. 2026;18(10):1580. https://doi.org/10.3390/cancers18101580
- 15.Tinsley SA, Dankerlui D, Romain C, Ruffin W, Brown E, Burnett C, et al. Increasing Prostate Cancer Education and Screening for Black Men in Southeastern Michigan: Your Prostate, Your Health. Journal of Cancer Education. 2025;40(6):875-885. https://doi.org/10.1007/s13187-025-02588-0
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Racial disparities in surveillance adequacy, progression and mortality | [1] | 2026 | Current evidence | Retrospective single-system cohort spanning 1995 to 2023. |
| Transition from surveillance to treatment and protocol variation | [9] [11] | 2026 | Current evidence | Multicenter retrospective cohorts, one Korean; protocols and populations may differ from U.S. practice. |
| Surveillance eligibility by region and residence | [13] | 2026 | Access | Upper-bound estimate under a broad definition using routinely collected data. |
| Resource use and costs of surveillance | [14] | 2026 | Current evidence | Ontario administrative data with matched comparison; costs in Canadian dollars. |
| Follow-up of elevated PSA after community outreach | [15] | 2025 | Continuum of care | Single outreach program with small numbers of elevated results. |
| Invitation method and data quality in risk-targeted outreach | [3] | 2026 | Access | Feasibility pilot in four London primary care networks. |
| Shared decision-making, decision aids and digital decision support | [4] [5] [6] [7] | 2026 | Equity and trust | Cross-sectional survey data, single-site trials and a Portuguese physician survey. |
| Survivorship access and lived experience of surveillance | [2] [10] [12] | 2026 | Public communication | Small mixed-methods sample, single-center cohort and synthesis of qualitative studies. |
| Barbershop-based outreach to Black men | [8] | 2026 | Equity and trust | HIV-focused pilot; referrals estimated and self-reported by barbers. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

